Skip to content
2000
Volume 33, Issue 5
  • ISSN: 0929-8673
  • E-ISSN: 1875-533X
file format text download EPUB
file format pdf download PDF
side by side viewer icon HTML

Abstract

Introduction

Chemotherapy remains essential despite advances in immunotherapy, radiotherapy, and biological therapy. However, the wide range of chemical drugs is limited by a narrow therapeutic index, low selectivity, and the development of resistance. In this regard, new high-efficiency drugs are in extremely high demand. The indazole moiety, a scaffold found in many biologically active compounds, was selected for use in new drug design.

Methods

Six new indazole derivatives were synthesized Suzuki-Miyaura coupling starting from bromoindazole. Their antiviral (against influenza A and SARS-CoV-2), antibacterial (against ), and antiproliferative activities (against neuroblastoma, glioma, leukemia cell lines) were evaluated . Acute toxicity was assessed in mice of both sexes single intragastric administration, with toxicometric parameters and pathomorphological changes studied.

Results

6-(1H-pyrazol-4-yl)-1H-indazole () suppressed the reproduction of the influenza virus at non-toxic doses to the MDCK cells and showed cytotoxicity against cancer cell lines, with an IC between 4 and 14 µM. However, it exhibited significant acute toxicity in mice (LD 40 mg/kg), causing systemic organ damage.

Discussion

Derivative demonstrated promising antiviral and antiproliferative activities but exhibited considerable acute toxicity . The antiviral efficacy, although lower than oseltamivir, is meaningful and justifies further optimization and investigation. Its antibacterial activity against adds to its potential as a multifunctional agent.

Conclusion

While derivative has shown potential as an antiviral and anticancer agent, its high toxicity highlights the need for further studies to define a safe and effective therapeutic window. Overall, the indazole scaffold remains a valuable platform for the development of new therapeutic compounds.

© 2026 The Author(s). Published by Bentham Science Publishers.
This is an open access article published under CC BY 4.0 https://creativecommons.org/licenses/by/4.0/legalcode
Loading

Article metrics loading...

/content/journals/cmc/10.2174/0109298673389070250822065247
2025-09-05
2026-02-23

  • From This Site

    /content/journals/cmc/10.2174/0109298673389070250822065247
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

/deliver/fulltext/cmc/33/5/CMC-33-5-08.html?itemId=/content/journals/cmc/10.2174/0109298673389070250822065247&mimeType=html&fmt=ahah

References

  1. KerruN. GummidiL. MaddilaS. GanguK.K. JonnalagaddaS.B. A review on recent advances in nitrogen- containing molecules and their biological applications.Molecules2020258190910.3390/molecules2508190932326131
     [Google Scholar]
  2. KabirE. UzzamanM. A review on biological and medicinal impact of heterocyclic compounds.Results. Chem.2022410060610.1016/j.rechem.2022.100606
     [Google Scholar]
  3. MermerA. KelesT. SirinY. Recent studies of nitrogen containing heterocyclic compounds as novel antiviral agents: A review.Bioorg. Chem.202111410507610.1016/j.bioorg.2021.10507634157555
     [Google Scholar]
  4. NadarS. KhanT. Pyrimidine: An elite heterocyclic leitmotif in drug discovery-synthesis and biological activity.Chem. Biol. Drug. Des.2022100681884210.1111/cbdd.1400134914188
     [Google Scholar]
  5. JampilekJ. Heterocycles in medicinal chemistry.Molecules.20192421383910.3390/molecules2421383931731387
     [Google Scholar]
  6. MatyuginaE.S. KochetkovS.N. KhandazhinskayaA.L. Synthesis and biological activity of aza and deaza analogues of purine nucleosides.Russ. Chem. Rev.202190111454149110.1070/RCR5013
     [Google Scholar]
  7. HeraviM.M. ZadsirjanV. Prescribed drugs containing nitrogen heterocycles: an overview.RSC Advances20201072442474431110.1039/D0RA09198G35557843
     [Google Scholar]
  8. QinJ. ChengW. DuanY.T. YangH. YaoY. Indazole as a privileged scaffold: The derivatives and their therapeutic applications.Anticancer. Agents Med. Chem.202121783986010.2174/187152062099920081816035032819234
     [Google Scholar]
  9. ZhangS.G. LiangC.G. ZhangW.H. Recent advances in indazole-containing derivatives: Synthesis and biological perspectives.Molecules.20182311278310.3390/molecules2311278330373212
     [Google Scholar]
  10. DenyaI. MalanS.F. JoubertJ. Indazole derivatives and their therapeutic applications: A patent review (2013-2017).Expert Opin. Ther. Pat.201828644145310.1080/13543776.2018.147224029718740
     [Google Scholar]
  11. GhoshS. MondalS. HajraA. Direct catalytic functionalization of indazole derivatives.Adv. Synth. Catal.2020362183768379410.1002/adsc.202000423
     [Google Scholar]
  12. PuriS. SawantS. JuvaleK. A comprehensive review on the indazole based derivatives as targeted anticancer agents.J. Mol. Struct.2023128413532710.1016/j.molstruc.2023.135327
     [Google Scholar]
  13. Al-TuwaijriH.M. Al-AbdullahE.S. El-RashedyA.A. AnsariS.A. AlmomenA. AlshiblH.M. HaibaM.E. AlkahtaniH.M. New indazol-pyrimidine-based derivatives as selective anticancer agents: Design, synthesis, and in silico studies.Molecules.2023289366410.3390/molecules2809366437175074
     [Google Scholar]
  14. BastosI.M. RebeloS. SilvaV.L.M. A comprehensive review on phosphatidylinositol-3-kinase (PI3K) and its inhibitors bearing pyrazole or indazole core for cancer therapy.Chem. Biol. Interact.202439811107310.1016/j.cbi.2024.11107338823538
     [Google Scholar]
  15. HoangV.H. TrangN.T.K. MinhT.C. LongL.T.B. LanT.H. HueN.T. TienL.Q. NguyenT.X. NguyenY.T.K. YooH. TranP.T. Design, synthesis and evaluation the bioactivities of novel 1,3-dimethyl-6-amino-1H-indazole derivatives as anticancer agents.Bioorg. Med. Chem.20239011737710.1016/j.bmc.2023.11737737352576
     [Google Scholar]
  16. QinQ. LuS. GuoZ. LiZ. FuQ. WangX. WuT. SunY. LiuN. zhangH. ZhaoD. ChengM. Discovery of novel indazole derivatives as second-generation TRK inhibitors.Eur. J. Med. Chem.202427611664010.1016/j.ejmech.2024.11664039033612
     [Google Scholar]
  17. WanY. HeS. LiW. TangZ. Indazole derivatives: Promising anti-tumor agents.Anticancer. Agents Med. Chem.20191891228123410.2174/187152061866618051011382229745343
     [Google Scholar]
  18. WangC. ZhuM. LongX. WangQ. WangZ. OuyangG. Design, synthesis and antitumor activity of 1H -indazole-3-amine derivatives.Int. J. Mol. Sci.20232410868610.3390/ijms2410868637240028
     [Google Scholar]
  19. HeoY.A. DugganS.T. Niraparib: A review in ovarian cancer.Target. Oncol.201813453353910.1007/s11523‑018‑0582‑130073633
     [Google Scholar]
  20. NguyenD.T. ShayahiS. Pazopanib: approval for soft-tissue sarcoma.J. Adv. Pract. Oncol.201341535725031981
     [Google Scholar]
  21. TsironisG. LiontosM. KyriazoglouA. KoutsoukosK. TsiaraA. KaparelouM. ZakopoulouR. CohenA. SkafidaE. FontaraS. ZagouriF. BamiasA. DimopoulosM.A. Axitinib as a third or further line of treatment in renal cancer: a single institution experience.BMC Urol.20202016010.1186/s12894‑020‑00618‑132487200
     [Google Scholar]
  22. DongJ. ZhangQ. WangZ. HuangG. LiS. Recent advances in the development of indazole-based anticancer agents.ChemMedChem201813151490150710.1002/cmdc.20180025329863292
     [Google Scholar]
  23. GopiB. VijayakumarV. An efficient and simple approach for synthesizing indazole compounds using palladium-catalyzed Suzuki–Miyaura cross-coupling.RSC Advances.20241436264942650410.1039/D4RA04633A39175677
     [Google Scholar]
  24. ParkY. PacittoA. BaylissT. CleghornL.A.T. WangZ. HartmanT. AroraK. IoergerT.R. SacchettiniJ. RizziM. DoniniS. BlundellT.L. AscherD.B. RheeK. BredaA. ZhouN. DartoisV. JonnalaS.R. ViaL.E. MizrahiV. EpemoluO. StojanovskiL. SimeonsF. Osuna-CabelloM. EllisL. MacKenzieC.J. SmithA.R.C. DavisS.H. MurugesanD. BuchananK.I. TurnerP.A. HuggettM. ZuccottoF. Rebollo-LopezM.J. Lafuente-MonasterioM.J. SanzO. DiazG.S. LelièvreJ. BallellL. SelenskiC. AxtmanM. Ghidelli-DisseS. PflaumerH. BöscheM. DrewesG. FreibergG.M. KurnickM.D. SrikumaranM. KempfD.J. GreenS.R. RayP.C. ReadK. WyattP. BarryC.E.III BoshoffH.I. Essential but not vulnerable: Indazole sulfonamides targeting inosine monophosphate dehydrogenase as potential leads against Mycobacterium tuberculosis.ACS Infect. Dis.201731183310.1021/acsinfecdis.6b0010327704782
     [Google Scholar]
  25. TenevaY. SimeonovaR. ValchevaV. AngelovaV.T. Recent advances in anti-tuberculosis drug discovery based on hydrazide–hydrazone and thiadiazole derivatives targeting inhA.Pharmaceuticals (Basel)202316448410.3390/ph1604048437111241
     [Google Scholar]
  26. ShaikhF. ArifM. KhushtarM. NematullahM. RahmanM.A. Synthesis and evaluation of antibacterial activity of novel 3-methyl-1H-indazole derivatives.Intelligent Pharmacy202421121610.1016/j.ipha.2023.09.003
     [Google Scholar]
  27. AsadN. LyonsM. Muniz Machado RodriguesS. BurnsJ. RoperT. LaidlawG. AhmadS. GuptonB. KlumppD. JinL. Practical synthesis of 7-bromo-4-chloro-1 H -indazol-3-amine: An important intermediate to lenacapavir.Molecules20242912270510.3390/molecules2912270538930779
     [Google Scholar]
  28. TurnerL.D. SummersA.J. JohnsonL.O. KnowlesM.A. FishwickC.W.G. Identification of an indazole-based pharmacophore for the inhibition of FGFR kinases using fragment-led de Novo design.ACS Med. Chem. Lett.20178121264126810.1021/acsmedchemlett.7b0034929259745
     [Google Scholar]
  29. TurnerL.D. TrinhC.H. HubballR.A. OrrittK.M. LinC.C. BurnsJ.E. KnowlesM.A. FishwickC.W.G. From fragment to lead: de novo design and development toward a selective FGFR2 inhibitor.J. Med. Chem.20226521481150410.1021/acs.jmedchem.1c0116334780700
     [Google Scholar]
  30. ZhongL. LiY. XiongL. WangW. WuM. YuanT. YangW. TianC. MiaoZ. WangT. YangS. Small molecules in targeted cancer therapy: advances, challenges, and future perspectives.Signal Transduct. Target. Ther.20216120110.1038/s41392‑021‑00572‑w34054126
     [Google Scholar]
  31. MatyuginaE. PetushkovI. SurzhikovS. KezinV. MaslovaA. IvanovaO. SmirnovaO. KirillovI. FedyakinaI. KulbachinskiyA. KochetkovS. KhandazhinskayaA. Nucleoside analogs that inhibit SARS- CoV-2 replication by blocking interaction of virus polymerase with RNA.Int. J. Mol. Sci.2023244336110.3390/ijms2404336136834771
     [Google Scholar]
  32. Manual for the laboratory diagnosis and virological surveillance of influenza.WHO Global Influenza Surveillance NetworkWHO Press2011
     [Google Scholar]
  33. FediakinaI.T. KonoplevaM.V. ProshinaE.S. LinnikE.V. NikitinaN.I. Antiviral effect of «Kagocel» substance in vitro on influenza viruses H1N1, H1N1pdm09 and H3N2.Vopr. Virusol.201964312513110.18821/0507‑4088‑2019‑64‑3‑125‑13131622059
     [Google Scholar]
  34. MatyuginaE. KhandazhinskayaA. ChernousovaL. AndreevskayaS. SmirnovaT. ChizhovA. KarpenkoI. KochetkovS. AlexandrovaL. The synthesis and antituberculosis activity of 5′-nor carbocyclic uracil derivatives.Bioorg. Med. Chem.201220226680668610.1016/j.bmc.2012.09.01923062712
     [Google Scholar]
  35. MatyuginaE. NovikovM. BabkovD. OzerovA. ChernousovaL. AndreevskayaS. SmirnovaT. KarpenkoI. ChizhovA. MurthuP. LutzS. KochetkovS. Seley-RadtkeK.L. KhandazhinskayaA.L. 5-arylaminouracil derivatives: New inhibitors of Mycobacterium tuberculosis.Chem. Biol. Drug Des.20158661387139610.1111/cbdd.1260326061192
     [Google Scholar]
  36. KhandazhinskayaA. EletskayaB. MironovA. KonstantinovaI. EfremenkovaO. AndreevskayaS. SmirnovaT. ChernousovaL. KondrashovaE. ChizhovA. Seley-RadtkeK. KochetkovS. MatyuginaE. New flexible analogues of 8-aza-7-deazapurine nucleosides as potential antibacterial agents.Int. J. Mol. Sci.202324201542110.3390/ijms24201542137895100
     [Google Scholar]
  37. LipatovaA.V. SobolevaA.V. GorshkovV.A. BubisJ.A. SolovyevaE.M. KrasnovG.S. KochetkovD.V. VorobyevP.O. IlinaI.Y. MoshkovskiiS.A. KjeldsenF. GorshkovM.V. ChumakovP.M. TarasovaI.A. Multi-omics analysis of glioblastoma cells’ sensitivity to oncolytic viruses.Cancers (Basel)20211321526810.3390/cancers1321526834771433
     [Google Scholar]
  38. NovikovaO.N. MatyuginaE.S. GorsheninA.V. VelikorodnayaY.I. KrengauzM.D. VedernikovaV.O. SpirinP.V. PrassolovV.S. KochetkovS.N. KhandazhinskayaA.L. 5′-noraristeromycin repurposing: Well- known S-adenosyl-L-homocysteine hydrolase inhibitor as a potential drug against leukemia.Acta Nat. (Engl. Ed.)2024163606639555174
     [Google Scholar]
  39. Voronina, T.A.; Guzeevatykh, L.S.; Mironov, A.N. Guidelines for conducting preclinical studies of drugs. Guidelines for the Study of the Analgesic Activity of Drugs/Edited., 2012,197-218.Grif and K, Moscow.2012197218
     [Google Scholar]
  40. DüfertM.A. BillingsleyK.L. BuchwaldS.L. Suzuki-Miyaura cross-coupling of unprotected, nitrogen-rich heterocycles: Substrate scope and mechanistic investigation.J. Am. Chem. Soc.201313534128771288510.1021/ja406446923909907
     [Google Scholar]
  41. MatyuginaE.S. KhandazhinskayaA.L. KochetkovS.N. Seley-RadtkeK.L. Synthesis of 3-hetarylpyrroles by Suzuki–Miyaura cross-coupling.Mendeleev Commun.202030223123210.1016/j.mencom.2020.03.034
     [Google Scholar]
  42. KhandazhinskayaA. EletskayaB. FateevI. KharitonovaM. KonstantinovaI. BaraiV. AzhayevA. HyvonenM.T. KeinanenT.A. KochetkovS. Seley-RadtkeK. KhomutovA. MatyuginaE. Novel fleximer pyrazole-containing adenosine analogues: Chemical, enzymatic and highly efficient biotechnological synthesis.Org. Biomol. Chem.202119347379738910.1039/D1OB01069G34198312
     [Google Scholar]
  43. Technical manual for culture-based drug susceptibility testing of antituberculosis drugs used in the treatment of tuberculosis.WHO operational handbook on tuberculosis. Module 3: diagnosis - rapid diagnostics for tuberculosis detection3rd ed.World Health OrganizationGeneva2024
     [Google Scholar]
  44. MerkulovG.A. Course in pathohistological technique.5th ed.Medicine. Leningrad DepartmentLeningrad1969
     [Google Scholar]
  45. Microscopic technique: Manual.MoscowMedicine1996
     [Google Scholar]
  46. FinneyD.J. Probit analysis. A statistical treatment of the sigmoid response curve./ D.J. Finney.CambridgeCambridge University Press1947
     [Google Scholar]
  47. HusainiR. AhmadM. ZakariaZ. Effectiveness of imatinib mesylate over etoposide in the treatment of sensitive and resistant chronic myeloid leukaemia cells in vitro. Exp. Ther. Med.20171363209321610.3892/etm.2017.444328587395
     [Google Scholar]
  48. ZhouZ. ZwellingL.A. GanapathiR. KleinermanE.S. Enhanced etoposide sensitivity following adenovirus-mediated human topoisomerase II α gene transfer is independent of topoisomerase II β.Br. J. Cancer200185574775110.1054/bjoc.2001.196611531262
     [Google Scholar]
  49. KluskaM. WoźniakK. Natural polyphenols as modulators of etoposide anti-cancer activity.Int. J. Mol. Sci.20212212660210.3390/ijms2212660234202987
     [Google Scholar]
  50. SlaterL. OsannK. EklofA. ArquillaE. StupeckyM. SweetP. Etoposide induction of tumor immunity in Lewis lung cancer.Cancer Chemother. Pharmacol.200148432733210.1007/s00280010035711710634
     [Google Scholar]
/content/journals/cmc/10.2174/0109298673389070250822065247
Loading
New Indazole Derivatives as Potential Scaffolds for the Development of Anticancer, Antiviral, and Anti-tuberculosis Chemotherapeutic Compounds
Curr. Med. Chem. 33, 1021 (2026); https://doi.org/10.2174/0109298673389070250822065247
/content/journals/cmc/10.2174/0109298673389070250822065247
/content/journals/cmc/10.2174/0109298673389070250822065247
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher’s website along with the published article.

file format download Download

  • Article Type:     Research Article
Keyword(s): anticancer activity; antiviral compounds; drug design; Indazole derivatives; inhibition; Mycobacterium tuberculosis

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test